Clinical Trial Update: Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 pediatric MATCH trial evaluating larotrectinib in patients with NTRK gene fusions has posted results; the study remains active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Glioma
• Medulloblastoma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Rhabdomyosarcoma
• Wilms Tumor

Drugs mentioned

• Larotrectinib (larotrectinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-16